AMCP believes in competitive marketplace solutions to lower costs for Americans and recognizes the critical need to address the rising cost of prescription medications. Rebates represent a way to negotiate drug discounts and constitute an important tool to control drug costs.
AMCP supports systems and processes that allow for clinical and economic information to be shared between manufacturers and health care decision-makers proactively and in a timely manner prior to FDA approval. A proactive PIE system would expedite coverage and utilization management policies for emerging therapies, including those granted breakthrough designation, providing earlier access for appropriate patients.
June 2021 News & Views: Register for AMCP's Annual eLearning Days; Medicaid Drug Rebate Program Best Price Rule Delayed; AMCP Foundation Executive Director Paula J. Eichenbrenner, MBA, CAE, Named as Alexandria Chamber of Commerce 40 Under 40 Honoree.
May 2021 News & Views: AMCP Introduces New Strategic Priorities; Defining Our Health Care Future; AMCP Sends Letter of Support for Chiquita Brooks-LaSure's Nomination; Congratulations to the 2021 Steven G. Avey Award Winner Babette Edgar, PharmD, MBA, FAMCP.
House Energy and Commerce Subcommittee Holds Hearing on Drug Pricing Legislation; AMCP Issues Statement Congratulating HHS Deputy Secretary Palm; AMCP Sends Letter to Senate Finance Committee in Support of Chiquita Brooks-Lasure.
